glp 1 addiction treatment Caron Pioneers Novel Use of GLP-1s in Treatment- Featured on the Front Page of The Washington Post GLP-1 drugs transform lives of

88.9%), and therapeutic inertia was observed in only 45 individuals (11.1%) (Table 6)

In November 2025, Novo Nordisk and Eli Lilly both reached similar deals with the Trump administration to sell the lowest dose of oral GLP-1 medications for $149 per month out of pocket

More recently, the buzz is around a new trend: micro-dosing these medications

Market restraints include premium pricing of pharmaceutical-grade and liposomal glutathione, driven by precision fermentation, stabilization technologies, and rigorous purity verification, which restrict access for cost-sensitive consumers

For more lifestyle news, follow us on Instagram | Twitter | Facebook and dont miss out on the latest updates!

Hosted by: Dave Crane - an award-winning keynote speaker, authority strategist, and founder of the Industry Icon Program and Thought Leaders Network